EA201401083A1 - Применение ингибиторов ccr3 - Google Patents
Применение ингибиторов ccr3Info
- Publication number
- EA201401083A1 EA201401083A1 EA201401083A EA201401083A EA201401083A1 EA 201401083 A1 EA201401083 A1 EA 201401083A1 EA 201401083 A EA201401083 A EA 201401083A EA 201401083 A EA201401083 A EA 201401083A EA 201401083 A1 EA201401083 A1 EA 201401083A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- eosinophilic
- denotes
- alkyl
- age
- macular degeneration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Structure Of Transmissions (AREA)
Abstract
В заявке описаны соединения формулы 1, которые являются ингибиторами CCR3где Rобозначает Н, C-C-алкил, C-C-алкил(C-С)циклоалкил, CСгалогеналкил, Rобозначает Н, C-C-алкил, X обозначает анион, выбранный из группы, включающей хлорид или 1/2 дибензоилтартрат, j равен 1 или 2, для применения в качестве лекарственного средства, предназначенного для лечения заболевания, выбранного из сухой формы возрастной дегенерации желтого пятна (dAMD), влажной формы возрастной дегенерации желтого пятна (wAMD), ретролентальной фиброплазии (ROP), окклюзии центральной вены сетчатки (CRVO), назального полипоза, эозинофильного эзофагита, эозинофильного гастроэнтерита (например, эозинофильного гастрита и эозинофильного энтерита), гиперэозинофильного синдрома и синдрома Черджа-Стросса.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937.2 | 2012-04-03 | ||
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201401083A1 true EA201401083A1 (ru) | 2015-03-31 |
| EA032263B1 EA032263B1 (ru) | 2019-05-31 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201401083A EA032263B1 (ru) | 2012-04-03 | 2013-04-02 | Применение ингибиторов ccr3 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (ru) |
| EP (3) | EP3763369B1 (ru) |
| JP (2) | JP2015512432A (ru) |
| KR (5) | KR20140144200A (ru) |
| CN (2) | CN110384699A (ru) |
| AU (1) | AU2013245027B2 (ru) |
| BR (1) | BR112014023795B1 (ru) |
| CA (1) | CA2869269C (ru) |
| CL (1) | CL2014002523A1 (ru) |
| CY (1) | CY1123222T1 (ru) |
| DK (1) | DK2833884T3 (ru) |
| EA (1) | EA032263B1 (ru) |
| ES (2) | ES2987267T3 (ru) |
| HR (1) | HRP20201165T1 (ru) |
| HU (1) | HUE051648T2 (ru) |
| IL (1) | IL234262A (ru) |
| IN (1) | IN2014DN06989A (ru) |
| LT (1) | LT2833884T (ru) |
| MX (1) | MX2014011786A (ru) |
| NZ (1) | NZ628882A (ru) |
| PH (1) | PH12014502239A1 (ru) |
| PL (1) | PL2833884T3 (ru) |
| PT (1) | PT2833884T (ru) |
| RS (1) | RS60665B1 (ru) |
| SI (1) | SI2833884T1 (ru) |
| SM (1) | SMT202000499T1 (ru) |
| WO (1) | WO2013149986A1 (ru) |
| ZA (1) | ZA201406082B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6684363B2 (ja) | 2016-11-24 | 2020-04-22 | キリシマ精工株式会社 | 歯列矯正具 |
| ES3046717T3 (en) * | 2017-04-05 | 2025-12-02 | Alkahest Inc | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
| EP3606525B1 (en) | 2017-04-05 | 2025-12-10 | Alkahest, Inc. | Compositions for treating aging-associated impairments using ccr3-inhibitors |
| CN111343983A (zh) * | 2017-10-13 | 2020-06-26 | 万能溶剂有限公司 | 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物 |
| BR112020023001A2 (pt) | 2018-05-15 | 2021-02-02 | Alkahest, Inc. | tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase |
| JP7528065B2 (ja) * | 2018-09-26 | 2024-08-05 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 |
| CA3180401A1 (en) * | 2020-06-11 | 2021-12-16 | Bartosz SIKORSKI | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| EP4426284A4 (en) | 2021-11-01 | 2025-11-12 | Alkahest Inc | Benzodioxane Leukotriene A4 Hydrolase (LTA4H) Modulators for the Prevention and Treatment of Age-Related Diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| EP1259615B1 (en) * | 2000-03-03 | 2008-11-12 | Cambridge Antibody Technology Limited | Antibodies against eotaxin and their use |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010138591A1 (en) * | 2009-05-26 | 2010-12-02 | University Of Kentucky Research Foundation | Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123222T1 (el) | Χρηση των υποδοχεων ccr3 | |
| EA202190137A1 (ru) | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| DK2970216T3 (da) | Biarylamidforbindelser som kinaseinhibitorer | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| EA201200952A1 (ru) | Производные пиразина и их применение для лечения неврологических нарушений | |
| EA201591906A1 (ru) | Производные мочевины, полезные в качестве ингибиторов киназы | |
| AR099489A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| JP2015512432A5 (ru) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| MX389142B (es) | Compuestos espiro triciclicos. | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| EA201690012A1 (ru) | Карбазолкарбоксамидные соединения | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια |